Market research
23I.F Intra-Cellular Therapies, Inc
F EUR Healthcare
Latest close
—
—
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 13B
- P/E ratio
- 0.0
- Analyst target
- 52.4
- Dividend yield
- Not available
- Beta
- 0.46
Community
Investor discussion
1 comment
Sign in to join the 23I.F discussion.
5 years, 5 months ago
Intra-Cellular Therapies, Inc is currently in a long term uptrend where the price is trading 25.4% above its 200 day moving average.
From a valuation standpoint, the stock is 91.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 107.5.
Intra-Cellular Therapies, Inc's total revenue rose by 20363.9% to $12M since the same quarter in the previous year.
Its net income has dropped by 49.6% to $-61M since the same quarter in the previous year.
Finally, its free cash flow fell by 91.3% to $-68M since the same quarter in the previous year.
Based on the above factors, Intra-Cellular Therapies, Inc gets an overall score of 3/5.